Merck’s Keytruda Further Entrenches Women’s Oncology Position With Cervical Cancer Results

Merck said the KEYNOTE-A18 trial in newly diagnosed, high-risk locally advanced patients met its PFS co-primary endpoint, while results for the OS endpoint were not yet mature.

Merck announced results from the Phase III KEYNOTE-A18 study in cervical cancer • Source: Shutterstock

Merck & Co., Inc. stands to expand its lead among PD-1 and PD-L1 checkpoint inhibitors in cancers affecting women with new interim Phase III results for Keytruda (pembrolizumab) in newly diagnosed, high-risk locally advanced cervical cancer, given the checkpoint inhibitor’s existing approvals in cervical cancer indications as well as in other gynecological cancers.

Without disclosing data, Merck announced on 19 July that in the KEYNOTE-A18 trial, Keytruda combined with external beam radiotherapy (EBRT)...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

AI-First, Big Pharma, Chinese Firms In Race - What’s Ahead For PRMT5 Inhibitors

 
• By 

As AI-driven firms like Insilico, big pharma like J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s respectively advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?

Actuate Is Looking For A Buyer To Advance Pancreatic Cancer Candidate

 

After presenting encouraging Phase II data on the GSK-3 inhibitor elraglusib at ASCO, Actuate Therapeutics is hoping to hold a pre-NDA meeting with the US FDA.

In Brief: Kezar Plots Lupus Revival For Zetomipzomib As FDA Lifts Hold On Hepatitis Trial

 
• By 

The go-ahead to resume a trial for its only drug candidate, zetomipzomib, in hepatitis could give Kezar a glimmer of hope of reviving another halted study in lupus nephritis.

AstraZeneca’s Amyloidosis Drug Fails In Phase III But Subgroup Hopes Persist

 

Anselamimab was expected to complement Alexion's portfolio of amyloid therapies, but regulators will have to be convinced of its benefits to a patient subgroup in the CARES trial.

More from R&D